Last reviewed · How we verify
RSO-021
At a glance
| Generic name | RSO-021 |
|---|---|
| Also known as | Thiostrepton |
| Sponsor | RS Oncology LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSO-021 CI brief — competitive landscape report
- RSO-021 updates RSS · CI watch RSS
- RS Oncology LLC portfolio CI